相关实验视频

Updated: Jun 21, 2025

CRISPR/Cas9-mediated Targeted Integration In Vivo Using a Homology-mediated End Joining-based Strategy

CRISPR/Cas9-mediated Targeted Integration In Vivo Using a Homology-mediated End Joining-based Strategy

Published on: March 12, 2018

在体内进行CRISPR基编辑,用于治疗亨廷顿病

Shraddha Shirguppe, Michael Gapinske, Devyani Swami

bioRxiv : the preprint server for biology

|July 15, 2024

概括

克里斯普尔基编辑为亨廷顿病 (HD) 治疗提供了一种新的方法. 这种方法设计了对有毒蛋白质碎片形成的抵抗力,减少了HD模型中的神经元损伤.

科学领域:

神经科学是一个神经科学.
遗传学遗传学是一个
分子生物学分子生物学

背景情况:

亨廷顿病 (HD) 是一种致命的神经退行性疾病.
它源于亨廷丁 (HTT) 基因中的扩大CAG重复.
突变HTT由酶-6的蛋白质分解分裂产生有毒碎片,这是一个关键的致病事件.

研究的目的:

研究CRISPR基编辑作为HD的治疗策略.
为了开发抗caspase-6裂变的HTT蛋白种类.
评估基准编辑在减少疾病病理方面的有效性.

主要方法:

选了141个CRISPR基编辑器变体,针对HTT基因拼接元素.
编辑了13号外子的拼接受体序列,以诱导外子跳转.
交付基础编辑器到动物高清模型的条纹体.

主要成果:

识别了产生对caspase-6蛋白解耐药的HTT异型的编辑器.
实现了高效的外跳转,并减少了N端碎片形成.
观察到HTT蛋白聚合的减少和减弱的条纹/皮层缩.

结论:

克里斯普尔基编辑显示了治疗亨廷顿病的潜力.
编辑HTT拼接元素可以减轻关键的致病机制.
这种方法可以减少突变HTT蛋白在HD中的毒性.

更多相关视频

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Published on: May 25, 2018

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells

Published on: September 25, 2019

相关概念视频

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...